ACW Appendix 4E and 2026 annual report
Filed with ASX · · 88 pages · English
Summary by 6ix AI
The company reported a decrease in revenue from ordinary activities compared to the previous year, alongside a notable increase in total expenses due to ramped-up clinical activities. Actinogen is developing Xanamem, a novel therapy aimed at treating Alzheimer’s disease and other neurological conditions, with pivotal trial results expected soon.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- June 2026 Quarterly activity report & Appendix 4C
- Xanamem depression trial published in British J Psychiatry
- ACW third positive XanaMIA trial data committee review
- Actinogen receives positive EMA scientific advice aligned with prior FDA guidance for its Alzheimer’s disease program
- Actinogen receives positive scientific advice from EMA
Later from Actinogen Medical
- ACW FY2026 results and outlook
- ACW unlisted options fully underwritten
- ACW Alzheimers pivotal trial completes last patient visit
- Underwriting of unlisted options completed
- Actinogen XanaMIA pivotal Alzheimer’s disease trial completes final patient visit, with topline results on track for November
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical